Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Adjunctive Intranasal Esketamine in Treatment-Resistant Depression

Adjunctive Intranasal Esketamine in Treatment-Resistant Depression Letters COMMENT & RESPONSE In Reply We thank Shouan and Grover for their interest in our recently published study. Regarding the question about the Adjunctive Intranasal Esketamine definition of treatment-resistant depression (TRD) used in the in Treatment-Resistant Depression study, we would like to emphasize that this was a proof-of- To the Editor We read with interest about the phase 2 ran- concept study to evaluate the dose response with intranasal domized clinical trial by Daly et al that evaluated the effi- esketamine. Larger phase 3 studies are required before the pa- cacy and safety of intranasal esketamine as an adjunctive tient population and the utility of esketamine can be fully treatment for patients with treatment-resistant depression evaluated in TRD. (TRD) during 130 days. We compliment the authors for a It is recognized that the definition of TRD is still evolving, robust methodology. However, we feel that the findings of and at this time, there still is not full global consensus on the the article must be interpreted in light of certain facts that appropriate definition. For example, current Committee for they have left unanswered. First, the authors defined TRD MedicinalProductsforHumanUseguidelinesfordevelopingnew on the basis of failure of 2 trials of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Psychiatry American Medical Association

Adjunctive Intranasal Esketamine in Treatment-Resistant Depression

JAMA Psychiatry , Volume 75 (6) – Jun 2, 2018

Loading next page...
 
/lp/american-medical-association/adjunctive-intranasal-esketamine-in-treatment-resistant-depression-0VXy4jMjJR
Publisher
American Medical Association
Copyright
Copyright 2018 American Medical Association. All Rights Reserved.
ISSN
2168-622X
eISSN
2168-6238
DOI
10.1001/jamapsychiatry.2018.0690
Publisher site
See Article on Publisher Site

Abstract

Letters COMMENT & RESPONSE In Reply We thank Shouan and Grover for their interest in our recently published study. Regarding the question about the Adjunctive Intranasal Esketamine definition of treatment-resistant depression (TRD) used in the in Treatment-Resistant Depression study, we would like to emphasize that this was a proof-of- To the Editor We read with interest about the phase 2 ran- concept study to evaluate the dose response with intranasal domized clinical trial by Daly et al that evaluated the effi- esketamine. Larger phase 3 studies are required before the pa- cacy and safety of intranasal esketamine as an adjunctive tient population and the utility of esketamine can be fully treatment for patients with treatment-resistant depression evaluated in TRD. (TRD) during 130 days. We compliment the authors for a It is recognized that the definition of TRD is still evolving, robust methodology. However, we feel that the findings of and at this time, there still is not full global consensus on the the article must be interpreted in light of certain facts that appropriate definition. For example, current Committee for they have left unanswered. First, the authors defined TRD MedicinalProductsforHumanUseguidelinesfordevelopingnew on the basis of failure of 2 trials of

Journal

JAMA PsychiatryAmerican Medical Association

Published: Jun 2, 2018

References